Quantcast

Hovione’s TwinCaps(R) Dry-powder Inhaler Approved in Japan as Part of Inavir(R) Influenza Treatment

September 14, 2010

LOURES, Portugal, September 14, 2010 /PRNewswire/ — Hovione is
announcing the approval in Japan of Inavir(R), Dry Powder Inhaler 20mg, for
treatment of influenza. This approval has been granted to Daiichi Sankyo
Company Ltd, a licensee of Hovione for the TwinCaps(R) inhaler which delivers
the drug to the lungs.

Hovione developed the TwinCaps(R) inhaler specifically for this
indication. Inavir(R) directly delivers the drug to the infected airways of
influenza patients, and a single inhaled dose has proven to be as effective
as a five-day course of oseltamivir for treatment of influenza. Daiichi
Sankyo has announced it is confident that Inavir(R) will be an important
alternative for treating influenza. According to Hovione, the low cost of the
device means the inhaler can be disposable and is thus ideally suited for the
treatment of lung infection. As bacteria or viruses are present in the
airways, a disposable inhaler may be safer than a re-usable one.

Peter Villax, TwinCaps(R) inventor and Hovione Vice-President said “This
approval will boost visibility for TwinCaps(R), an inhaler designed for
extreme ease of use, as would be necessary in the case of a pandemic.”

Jason Suggett, Hovione Director of Pharma Operations said “We have a
number of inhaled drug product development projects ongoing, and our in-house
particle engineering expertise means that we can deliver large doses of
powder from inhaler devices.”

About Hovione. Hovione is a leading developer of inhaled drug products,
with experience in anti-virals and proteins delivered by inhalation, as well
as inhaler development. It is an international company with 51 years’
experience in Active Pharmaceutical Ingredient integrated development and
compliant manufacture, from molecule to unit dose. In the inhalation area,
Hovione is the only independent company offering such a broad range of
services.

For more information about Hovione, please visit the Hovione site at
http://www.hovione.com or contact Corporate Communications, Isabel Pina,
+351-21-982-9362, e-mail: ipina@hovione.com.

SOURCE Hovione


Source: newswire



comments powered by Disqus